肺癌组织样本和血液样本EGFR基因检测对比研究

doi:10.3969/j.issn.1004-616x.2023.01.004

Abstract

Abstract: OBJECTIVE: To detect expression of the EGFR gene in lung adenocarcinomas so as to understand EGFR gene mutation in patients. METHODS: From July 1，2016 to December 1，2017，a total of 175 patients with stage III-IV lung adenocarcinomas who were admitted to our hospital were collected. Among them，all patients provided blood samples，119 provided tissue biopsy samples，175 provided plasma samples and 12 provided pleural fluid sediment cell samples. EGFR gene detection was performed on these samples using ARMS-PCR. Differences in results among the different types of samples and their relationships with patients' clinicopathological data were analyzed. RESULTS: Detection of EGFR gene expression was conducted on all blood and tissue samples. The total positive rate was 8.6% higher in the tissues than in that of blood samples and 3.1% higher than that in paraffin block tissues. EGFR mutation was found in different sex ((χ²=3.451，P=0.045)，tumor size ((χ²=8.911，P=0.002)，T stage ((χ²=17.567，P=0.000)，lymph node metastasis ((χ²=18.511，P=0.000)，metastasis station ((χ²=3.341，P=0.047) and distant metastasis ((χ²=10.874，P=0.001). EGFR mutation rates in blood and tissue samples were compared，and the difference was statistically significant (P=0.000). Tumor size [95%CI(0.151，0.725)，P=0.006]，lymph node metastases [95%CI(0.180，0.865)，P=0.020]，distant metastases [95%CI(0.097，0.612)，P=0.003] were important factors affecting progression-free survival. CONCLUSION: The combined application of samples from different tissues was useful in enhancing detection of EGFR gene expression. In addition，higher detection rate can increase the number of patients who are suitable for EGFR-tyrosine kinase inhibitors (TKIs) treatment in clinical practice. For female patients，the incidence of blood EGFR mutation was higher in those with tumor diameter ≥3 cm，stage T4，lymph node metastases with more than 3 stations，and distant metastases. Patients with tumor diameter ≥3 cm，lymph node metastasis and distant metastasis had shorter progression-free survival.

Key words: lung adenocarcinoma, EGFR gene, plasma samples, biopsy tissue samples, pleural fluid sediment cell samples, comparative study

CLC Number:

R365

DENG Huiyan, LIU Chang, JIA Ying, LI Fang, YIN Danjing, TAN Zirui, SU Bing, LIU Yueping. Comparative detection of the EGFR gene in lung adenocarcinoma tissues and blood samples[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 21-25.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] 曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志:电子版, 2021, 13(3):63-69.
[3] 康丽菲, 郑杰, 朱翔. EGFR基因突变与肺腺癌主要病理分型及标本类型的关系[J]. 中国肺癌杂志, 2017, 20(6):382-388.
[4] WU Y L, ZHOU C C, HU C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6):an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(2):213-222.
[5] RUSSO A, FRANCHINA T, RICCIARDI G R R, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC:where are we now and where are we going[J]. Crit Rev Oncol Hematol, 2017, 117:38-47.
[6] SUDA K, MURAKAMI I, SAKAI K, et al. Small cell lung cancer transformation and T790M mutation:complimentary roles in acquired resistance to kinase inhibitors in lung cancer[J]. Sci Rep, 2015, 5:14447.
[7] BARLESI F, MAZIERES J, MERLIO J P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer:results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)[J]. Lancet, 2016, 387(10026):1415-1426.
[8] WAN J C M, MASSIE C, GARCIA-CORBACHO J, et al. Liquid biopsies come of age:towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4):223-238.
[9] LYNCH T J, BELL D W, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21):2129-2139.
[10] 黄健, 王于理, 代平, 等. 胸水、血液EGFR基因突变检测在非小细胞肺癌治疗中的应用价值[J]. 山东医药, 2018, 58(6):61-63.
[11] 师艺, 马志萍, 崔文丽, 等. 肺腺癌活检组织、胸水及血液中表皮生长因子受体基因突变检测的比较分析[J]. 中华病理学杂志, 2018, 47(10):775-779.
[12] 王恩华, 朱明华, 步宏, 等. 非小细胞肺癌靶向药物治疗相关基因检测的规范建议[J]. 中华病理学杂志, 2016, 45(2):73-77.
[13] LINDEMAN N I, CAGLE P T, AISNER D L, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors[J]. J Mol Diagn, 2018, 20(2):129-159.
[14] 陈一峰, 陈婷, 陈玮姗, 等. 胸水细胞蜡块在肺癌诊断和EGFR基因检测中的应用研究[J]. 中国现代医学杂志, 2018, 28(29):43-46.
[15] 李志阳, 张志杰, 谭小军, 等. 非小细胞肺癌患者表皮生长因子受体基因突变的异质性[J]. 实用医学杂志, 2017, 33(6):983-985.
[16] THRESS K S, BRANT R, CARR T H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma:a cross-platform comparison of leading technologies to support the clinical development of AZD9291[J]. Lung Cancer, 2015, 90(3):509-515.

Comparative detection of the EGFR gene in lung adenocarcinoma tissues and blood samples

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments

[1]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[2]	ZENG Zhuoying, WU Desheng, LU Jingjing, LIAO Hui, LAI Hongpiao, YUAN Jianhui, HU Zhangli. Mediation by estrogen receptor α on oxidative phosphorylation pathways in development of lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 262-268.
[3]	DU Qiang, YAO Yiyong, ZENG Gang. Expression and clinical significance of ASPM in lung adenocarcinoma according to the TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 457-463.
[4]	MA Yang, WU Juan, JI Xiaokun, WANG Rui, DU Yun, WANG Heng, GUO Xiao, ZHANG Yan. Silencing EGFR expression influenced autophagy activity in A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 347-351,358.
[5]	GUO Xiao, WANG Rui, WU Juan, JI Xiaokun, WANG Heng, ZHANG Yan, MA Yang, DU Yun. Significance of EGFR gene mutation in fresh cytological specimens of lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(1): 67-70.
[6]	LI Yuxuan, LI Kai, ZHANG Tongtong, GUO Yuanbiao, YIN Jun, BAO Yong. Heat shock protein HDJ1 on invasion and migration ability of lung adenocarcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(5): 358-363.
[7]	WU Juan, DU Yun, WANG Heng, WU Jianing, ZHAO Yinhuan, WANG Rui, ZHANG Yan, JI Xiaokun. Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 27-31.
[8]	LI Yu, YANG Su-xia, ZHOU Shu-zhen, et al. Experimental Study of Anti-tumor Effect of Baofeixiaoliu Capsule on Lung Adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2004, 16(1): 33-35.